The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Comments Help Inform ICER Assessment of Treatments for Lupus Nephritis & Other Rheumatic Conditions

ACR Comments Help Inform ICER Assessment of Treatments for Lupus Nephritis & Other Rheumatic Conditions

October 19, 2020 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

For example, in the lupus nephritis assessment currently underway, ICER is evaluating the clinical and economic value of two medical therapies not yet approved by the FDA: voclosporin and belimumab. In its September letter to ICER, the ACR raised concerns about the lack of head-to-head or real-world data comparisons to these new therapies. To better assess the efficacy of these new therapies, the ACR urged ICER to consider trends seen in the standard-of-care arms of clinical trials of the new therapies and incorporate data on flares, end-stage renal disease, need for steroid rescue, dropouts or treatment failures and deaths.

You Might Also Like
  • ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
  • Institute for Clinical Economic Review Final Report on RA Treatments
Also By This Author
  • ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront

The ACR has a good relationship with ICER despite questions about the methodology used, Dr. Phillips stresses. However, he expresses ongoing concerns about the ramifications of ICER’s conclusions, such as whether patients may lose access to treatment if insurance decides not to cover a drug that doesn’t meet the formal cost/QALY threshold used in an ICER assessment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We have found ICER to be fairly even-handed in [its] assessment of the data, and [it has] a genuine interest in helping to drive drug pricing to more rational levels,” Dr. Phillips says. “While we continue to be wary of whether the conclusions may be used by payers to be more restrictive to drug access, we have found [ICER] receptive to our input.”


Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: American College of Rheumatology Tagged With: Dr. Chris Phillips, Dr. Douglas White, Institute for Clinical and Economic Review (ICER), Lupus nephritis

You Might Also Like:
  • ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
  • Institute for Clinical Economic Review Final Report on RA Treatments
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)